Skip to content
OpenCapital
Get started

Opus Genetics IRD Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.1%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's cash provided by (used in) financing activity, including discontinued operation?
Opus Genetics (IRD) reported cash provided by (used in) financing activity, including discontinued operation of $27.6M in Q1 2026.
How has Opus Genetics's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Opus Genetics's cash provided by (used in) financing activity, including discontinued operation increased by 34.8% year-over-year, from $20.47M to $27.6M.
What is the long-term trend for Opus Genetics's cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), Opus Genetics's cash provided by (used in) financing activity, including discontinued operation has grown at a 16.0% compound annual growth rate (CAGR), from $27.61M to $50.02M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.